描述FDA批准的人工智能医疗设备的行业支付情况
Alon Bergman1,2,3, Tej A Patel4,5, Kaustav P Shah3,6,7
1Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA 19104, United States.
Health affairs scholar
|December 8, 2025
概括
工业对支持人工智能的医疗设备 (AIMD) 的支付正在上升,并集中在专业领域. 这种趋势可能会加剧医疗保健获取不平等,需要监测和支持公平的AIMD分配.
科学领域:
- 医疗技术 医疗技术 医学技术
- 医疗信息学 医疗信息学
- 医疗保健经济学 医疗经济学
背景情况:
- 支持人工智能的医疗设备 (AIMD) 在全球范围内越来越多地被使用.
- 有关在资源充足和资源不足的医疗保健机构之间公平获得AIMD存在担忧.
- 在AIMD生态系统中的行业-临床医生合作伙伴关系尚未得到充分理解.
研究的目的:
- 分析行业支付给FDA批准的AIMDs的临床医生的财务情况.
- 调查与这些支付相关的分配,市场集中和机构关联.
- 确定影响AIMD部门支付流动的因素.
主要方法:
- 利用开放支付数据库提取2017-2023年的支付数据.
- 使用医疗保险提供者数据目录将临床医生支付数据链接到医院附属机构.
- 使用回归分析将支付与医院和县级特征相关联.
主要成果:
- 针对AIMD的行业支付总额达到5930万美元,支付给46315名临床医生.
- AIMD支付占医疗器械行业支付总额的比例越来越大.
- 付款集中在技术先进的医学专业和大型城市教学医院的临床医生.
结论:
- 工业对AIMD的支付正在增加,并集中在专门的医疗领域.
- 大型非农村教学医院的临床医生更有可能获得AIMD支付.
- 公平获得AIMD可能需要持续的支付监控,透明的报告和有针对性的支持.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
219
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
219
FDA Approved Drugs: Changes to Approved Drugs
231
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
231
Bioequivalence studies: Biowaivers
210
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
210


